| Communicable Diseases |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
NCT02031133: Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C |
|
|
| Active, not recruiting | 2 | 10 | US | Miravirsen | Santaris Pharma A/S | Hepatitis C | 01/17 | 01/17 | | |
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program |
|
|
| No Longer Available | N/A | | US | Atazanavir (BMS-232632) | Bristol-Myers Squibb | HIV Infections | | 07/03 | | |
NCT00096811: Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program |
|
|
| No Longer Available | N/A | | RoW | Entecavir, Baraclude | Bristol-Myers Squibb | Hepatitis B, Chronic Disease | 08/08 | 08/08 | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
| No Longer Available | N/A | | Europe, RoW | Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin | Janssen-Cilag International NV | Hepatitis C | | | | |
|
|
|
|
|
|
|
|
|
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | Europe | Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
|
|
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | US | Daclatasvir (BMS-790052), Sofosbuvir | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
| No Longer Available | N/A | | RoW | Technetium labelled glucosamine | University of Sydney, AbbVie | Rheumatoid Arthritis, Ankylosing Spondylitis | | | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
| Recruiting | N/A | 500 | US | FilmArray | University of Nebraska, BioFire Diagnostics, LLC | Lower Respiratory Tract Infection | 12/17 | 12/17 | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |
DAD, NCT01238276: Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion |
|
|
| No Longer Available | N/A | | US | Cefazolin, Ancef, Kefzol, Silberg Tissue Preparation System, Silberg TPS (K023083), Tissue Preparation System, TPS, Mettler ME800 | Sonescence, Inc. | Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer | | | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease |
|
|
| No Longer Available | N/A | | NA | Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230 | Atara Biotherapeutics | CMV Viremia, CMV Disease | | | | |
NCT02557308: An Observational Study to Evaluate Safety and Efficacy of Remsimaâ„¢ in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | N/A | 1000 | RoW | | Celltrion | Ankylosing Spondylitis | 06/20 | 06/26 | | |
NCT02427308: Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry |
|
|
| Recruiting | N/A | 2 | US | Miltefosine | Knight Therapeutics (USA) Inc | Leishmaniasis or Other Uses of Miltefosine | 03/25 | 03/26 | | |